PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.41%
Revenue growth under 50% of ADI's 5.77%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-0.40%
Negative gross profit growth while ADI is at 5.38%. Joel Greenblatt would examine cost competitiveness or demand decline.
3.22%
EBIT growth below 50% of ADI's 7.73%. Michael Burry would suspect deeper competitive or cost structure issues.
3.22%
Operating income growth under 50% of ADI's 7.73%. Michael Burry would be concerned about deeper cost or sales issues.
-11.18%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-10.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-10.20%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.53%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.52%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.23%
Dividend reduction while ADI stands at 0.48%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-19.03%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-41.00%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
83.22%
10Y revenue/share CAGR at 75-90% of ADI's 110.02%. Bill Ackman would press for new markets or product lines to narrow the gap.
87.61%
5Y revenue/share CAGR 1.25-1.5x ADI's 62.30%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
27.99%
3Y revenue/share CAGR at 75-90% of ADI's 37.29%. Bill Ackman would expect new product strategies to close the gap.
99.01%
10Y OCF/share CAGR in line with ADI's 101.98%. Walter Schloss would see both as similarly efficient over the decade.
79.80%
5Y OCF/share CAGR is similar to ADI's 79.58%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
-22.36%
Negative 3Y OCF/share CAGR while ADI stands at 11.87%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
1239.80%
Net income/share CAGR above 1.5x ADI's 196.25% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
536.36%
5Y net income/share CAGR above 1.5x ADI's 134.12%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
15.83%
Below 50% of ADI's 44.46%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
98.52%
10Y equity/share CAGR in line with ADI's 108.32%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
19.49%
Positive 5Y equity/share CAGR while ADI is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
7.75%
Positive short-term equity growth while ADI is negative. John Neff sees a strong advantage in near-term net worth buildup.
373.94%
Dividend/share CAGR of 373.94% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
367.18%
Dividend/share CAGR of 367.18% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
298.29%
3Y dividend/share CAGR 1.25-1.5x ADI's 201.16%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
8.51%
Our AR growth while ADI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
4.63%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.36%
Positive asset growth while ADI is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
1.83%
1.25-1.5x ADI's 1.46%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
-5.06%
Our R&D shrinks while ADI invests at 3.95%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.61%
We cut SG&A while ADI invests at 3.82%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.